Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
37.98
-0.20 (-0.52%)
4:05:27 PM EDT: $37.95 -0.03 (-0.08%)
Products, Strategic Combinations, Regulatory

Springworks Therapeutics Announces Clinical Collaboration With Pfizer Inc To Evaluate Nirogacestat In Combination With Pf‐06863135 In Patients With Relapsed Or Refractory Multiple Myeloma

Published: 10/05/2020 11:05 GMT
Pfizer Inc (PFE) - Springworks Therapeutics Announces Clinical Collaboration With Pfizer Inc. to Evaluate Nirogacestat in Combination With Pf‐06863135 in Patients With Relapsed Or Refractory Multiple Myeloma.
Springworks Therapeutics - Pfizer and Co Will Also Form Joint Development Committee to Manage Clinical Study Which is Expected to Commence in H1 2021.
Springworks Therapeutics - Pfizer to Sponsor, Conduct Phase 1b/2 Study to Evaluate Safety, Tolerability & Prelim Efficacy of Nirogacestat Combination.
Springworks Therapeutics - Also Currently Conducting Global Phase 3 Clinical Trial to Evaluate Nirogacestat in Adults With Progressing Desmoid Tumors.